GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer

Carlo Milandri, Rolando Polico, Domenico Garcea, Alessando Passardi, Andrea Gardini, Antonino Romeo, Emanuela Scarpi, Paola Rosetti, Laura Ridolfi, Giuliano La Barba, Marianna Ricci, Dino Amadori

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aims: The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer. Methodology: Between November 2004 and July 2008, 33 enrolled patients received gemcitabine (GEM) 1000mg/m2 on day 1, and oxaliplatin (OX) 100mg/m2 on day 2, every two weeks for 3-4 cycles. This was followed by radiotherapy (25Gy, 5 fractions), 15 days after completion of GEMOX. Patients then received a further 3-4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received further GEMOX and radiotherapy. Results: Toxicity to GEMOX was similar to that reported elsewhere and radiotherapy was also well tolerated. After treatment, one patient achieved a complete response, 14 had a partial response, 11 showed a stable disease, 6 progressed, and one was not evaluable. Eight patients (24%) underwent surgical laparotomy (7 radical pancreatic resections and one explorative laparotomy). Conclusions: Our study shows the feasibility and potential efficacy of the GEMOX plus helical tomotherapy regimen in unresectable locally advanced pancreatic cancer.

Original languageEnglish
Pages (from-to)599-603
Number of pages5
JournalHepato-Gastroenterology
Volume58
Issue number106
Publication statusPublished - Mar 2011

Fingerprint

Pancreatic Neoplasms
Intensity-Modulated Radiotherapy
oxaliplatin
Radiotherapy
gemcitabine
Laparotomy
Feasibility Studies
Therapeutics

Keywords

  • GEMOX
  • Locally advanced pancreatic cancer
  • Neoadjuvant therapy
  • Radiotherapy

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Milandri, C., Polico, R., Garcea, D., Passardi, A., Gardini, A., Romeo, A., ... Amadori, D. (2011). GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. Hepato-Gastroenterology, 58(106), 599-603.

GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. / Milandri, Carlo; Polico, Rolando; Garcea, Domenico; Passardi, Alessando; Gardini, Andrea; Romeo, Antonino; Scarpi, Emanuela; Rosetti, Paola; Ridolfi, Laura; La Barba, Giuliano; Ricci, Marianna; Amadori, Dino.

In: Hepato-Gastroenterology, Vol. 58, No. 106, 03.2011, p. 599-603.

Research output: Contribution to journalArticle

Milandri, C, Polico, R, Garcea, D, Passardi, A, Gardini, A, Romeo, A, Scarpi, E, Rosetti, P, Ridolfi, L, La Barba, G, Ricci, M & Amadori, D 2011, 'GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer', Hepato-Gastroenterology, vol. 58, no. 106, pp. 599-603.
Milandri, Carlo ; Polico, Rolando ; Garcea, Domenico ; Passardi, Alessando ; Gardini, Andrea ; Romeo, Antonino ; Scarpi, Emanuela ; Rosetti, Paola ; Ridolfi, Laura ; La Barba, Giuliano ; Ricci, Marianna ; Amadori, Dino. / GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. In: Hepato-Gastroenterology. 2011 ; Vol. 58, No. 106. pp. 599-603.
@article{2f5a92d724f14b82ad2ed0e7a8d59a25,
title = "GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer",
abstract = "Background/Aims: The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer. Methodology: Between November 2004 and July 2008, 33 enrolled patients received gemcitabine (GEM) 1000mg/m2 on day 1, and oxaliplatin (OX) 100mg/m2 on day 2, every two weeks for 3-4 cycles. This was followed by radiotherapy (25Gy, 5 fractions), 15 days after completion of GEMOX. Patients then received a further 3-4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received further GEMOX and radiotherapy. Results: Toxicity to GEMOX was similar to that reported elsewhere and radiotherapy was also well tolerated. After treatment, one patient achieved a complete response, 14 had a partial response, 11 showed a stable disease, 6 progressed, and one was not evaluable. Eight patients (24{\%}) underwent surgical laparotomy (7 radical pancreatic resections and one explorative laparotomy). Conclusions: Our study shows the feasibility and potential efficacy of the GEMOX plus helical tomotherapy regimen in unresectable locally advanced pancreatic cancer.",
keywords = "GEMOX, Locally advanced pancreatic cancer, Neoadjuvant therapy, Radiotherapy",
author = "Carlo Milandri and Rolando Polico and Domenico Garcea and Alessando Passardi and Andrea Gardini and Antonino Romeo and Emanuela Scarpi and Paola Rosetti and Laura Ridolfi and {La Barba}, Giuliano and Marianna Ricci and Dino Amadori",
year = "2011",
month = "3",
language = "English",
volume = "58",
pages = "599--603",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "106",

}

TY - JOUR

T1 - GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer

AU - Milandri, Carlo

AU - Polico, Rolando

AU - Garcea, Domenico

AU - Passardi, Alessando

AU - Gardini, Andrea

AU - Romeo, Antonino

AU - Scarpi, Emanuela

AU - Rosetti, Paola

AU - Ridolfi, Laura

AU - La Barba, Giuliano

AU - Ricci, Marianna

AU - Amadori, Dino

PY - 2011/3

Y1 - 2011/3

N2 - Background/Aims: The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer. Methodology: Between November 2004 and July 2008, 33 enrolled patients received gemcitabine (GEM) 1000mg/m2 on day 1, and oxaliplatin (OX) 100mg/m2 on day 2, every two weeks for 3-4 cycles. This was followed by radiotherapy (25Gy, 5 fractions), 15 days after completion of GEMOX. Patients then received a further 3-4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received further GEMOX and radiotherapy. Results: Toxicity to GEMOX was similar to that reported elsewhere and radiotherapy was also well tolerated. After treatment, one patient achieved a complete response, 14 had a partial response, 11 showed a stable disease, 6 progressed, and one was not evaluable. Eight patients (24%) underwent surgical laparotomy (7 radical pancreatic resections and one explorative laparotomy). Conclusions: Our study shows the feasibility and potential efficacy of the GEMOX plus helical tomotherapy regimen in unresectable locally advanced pancreatic cancer.

AB - Background/Aims: The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer. Methodology: Between November 2004 and July 2008, 33 enrolled patients received gemcitabine (GEM) 1000mg/m2 on day 1, and oxaliplatin (OX) 100mg/m2 on day 2, every two weeks for 3-4 cycles. This was followed by radiotherapy (25Gy, 5 fractions), 15 days after completion of GEMOX. Patients then received a further 3-4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received further GEMOX and radiotherapy. Results: Toxicity to GEMOX was similar to that reported elsewhere and radiotherapy was also well tolerated. After treatment, one patient achieved a complete response, 14 had a partial response, 11 showed a stable disease, 6 progressed, and one was not evaluable. Eight patients (24%) underwent surgical laparotomy (7 radical pancreatic resections and one explorative laparotomy). Conclusions: Our study shows the feasibility and potential efficacy of the GEMOX plus helical tomotherapy regimen in unresectable locally advanced pancreatic cancer.

KW - GEMOX

KW - Locally advanced pancreatic cancer

KW - Neoadjuvant therapy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=79958165537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958165537&partnerID=8YFLogxK

M3 - Article

C2 - 21661438

AN - SCOPUS:79958165537

VL - 58

SP - 599

EP - 603

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 106

ER -